AstraZeneca Stock Jumps to $161.59 as Rising Yields Push Money Into a 0.21-Beta Pharma Trading 24% Below Its $212.71 High — $169 Next

AstraZeneca is one of the few large-cap stocks moving firmly higher on a day when hot US inflation hit most of the market. By 11:07 a.m. ET, the NYSE-listed shares traded at $161.59, up $5.77, or 3.70%, from Tuesday’s close of $155.82. The stock opened at $158.71, traded between $158.31 and $161.72, and had turned over 973,761 shares by late morning. By 12:32 p.m. ET, the gain had widened to 4.02%, putting the shares near $162.14.

The London listing confirmed the move. In the primary market, AstraZeneca rose 390 pence, or 3.28%, to 12,286p by 4:03 p.m. BST, after opening at 11,820p and trading as low as 11,816p. That close put the London market capitalization at £184.5 billion. AstraZeneca was among the FTSE 100’s notable gainers on a day the index climbed 0.7%.

The bounce comes from a deep base. The US-listed shares had traded at $155.82 on Tuesday, just 1.6% above the 52-week low of $153.41. The 52-week high stands at $212.71, which puts Wednesday’s price 24% below the peak. In London, the stock sits 22% below its 15,732p high and 24% above its 9,892p low. Over the past few weeks, the shares slid from the $166 to $169 area toward the mid-$150s before bouncing back to around $162.14.

The context makes the move notable. The S&P 500 fell 0.82% and the Nasdaq Composite dropped 1.14% by late morning after September consumer prices rose 3.7% year over year and the 10-year Treasury yield jumped to 5.278%. Healthcare was the exception: the Dow held near flat because of gains in UnitedHealth and Amgen, and Eli Lilly, Amgen and AbbVie all rose more than 2.8%.

The thesis for this forecast is direct: AstraZeneca is a high-quality defensive grower priced near its 52-week low, and Wednesday’s rotation into healthcare exposed how cheap it has become. Core earnings grew 11% in the first half, oncology revenue grew 15%, and management reaffirmed full-year guidance and its $80 billion 2030 revenue ambition. Yet the stock trades at 23.75 times trailing earnings after falling 21% in six months on generic competition and two high-profile trial disappointments. With a beta of 0.21 and a 2.00% dividend yield, AZN is exactly what investors want when the bond market turns hostile to growth stocks.

That framing puts $166 to $169 at the center of the near-term picture, the zone from which the stock broke down this month. Below, $155.82 and the $153.41 52-week low form the floor that buyers defended. The October 30 third-quarter report is the next major catalyst.

Why AZN Is Up: Defensive Rotation, a Double Upgrade and Easing UK Rate Fears

Three forces converged to lift AstraZeneca on Wednesday, and only one of them was company-specific.

The first is sector rotation. US inflation data showed consumer prices rising 0.6% in September and 3.7% year over year, above the 3.6% forecast, with core inflation at 2.6%. The 10-year Treasury jumped more than 6 basis points to 5.278%, and the odds of an October Fed rate hike rose sharply. Long-duration growth stocks sold off hardest, while investors moved into sectors with stable cash flows and low sensitivity to economic cycles. Healthcare carried the Dow: Eli Lilly rose 3.38%, Amgen 3.18% and AbbVie 2.80%. AstraZeneca’s 3.70% gain fits that pattern.

The second is a ratings change. On October 13, AstraZeneca received a double upgrade from Sell to Buy, with the price target raised to SEK 1,900 from SEK 1,650. The upgrade cited investor focus returning to the company’s heart-disease pipeline. A move from Sell straight to Buy is rare and signals a sharp change in view, typically after a stock has fallen enough to reset expectations. Earlier in the month, other brokers reaffirmed Buy ratings with London targets of 17,500p and 18,600p, the latter raised from 17,800p.

The third is the UK backdrop. London stocks ended higher on Wednesday, with the FTSE 100 climbing 0.7% despite the hot US inflation figures, as comments from the Bank of England’s chief economist eased concerns over aggressive UK rate increases. Huw Pill said he was more skeptical about market pricing of four rate hikes over the next year. AstraZeneca, the largest company on the FTSE 100, benefited directly from that shift, alongside GSK.

The timing reflects positioning. AstraZeneca had traded near its 52-week low through most of October, after a mixed Phase III result on October 11 added to concerns from earlier pipeline setbacks. Despite those trial results, the shares were trading near the $153 low, down 21% over the past six months. A stock that has been sold that heavily tends to rally hard when the narrative turns.

There is also an oncology angle. AstraZeneca has been trading higher after positive late-stage oncology developments boosted investor optimism, and the company has accelerated its deal-making in cancer through its $2 billion Summit Therapeutics investment.

For the forecast, Wednesday’s move is driven mostly by macro rotation and a ratings reset rather than new fundamental data. That makes it vulnerable if rates reverse. But it also shows that buyers are willing to step in near $155, establishing a credible floor.

H1 2026: $30.7 Billion Revenue, $5.21 Core EPS and an 84% Gross Margin

The underlying business is growing, and the first-half results show it clearly.

AstraZeneca’s H1 and Q2 2026 results, reported on July 27, showed total revenue of $30.672 billion, up 9% on a reported basis and 6% at constant exchange rates. Core earnings per share reached $5.21, up 12% reported and 11% at constant currency. Core operating profit totaled $10.5 billion, also up 11%. Reported EPS came in at $3.60, up 4%.

The second quarter showed acceleration in profitability. Q2 revenue reached $15.384 billion, up 6% reported and 5% at constant currency. Core EPS for the quarter hit $2.63, up 21% reported and 18% at constant currency, well ahead of revenue growth due to improved gross margins and expense discipline. The first quarter had delivered revenue of $15.288 billion, up 8% at constant currency, with core EPS of $2.58.

Margins expanded. AstraZeneca maintained a core gross margin of 83% in the first half, with the second quarter improving to 84%. On an annual basis, the company produces $58.7 billion in revenue with an 81.9% gross margin and a 23.3% EBIT margin. Those margins are among the highest in large-cap pharmaceuticals and reflect the shift toward specialty medicines in oncology and rare disease.

Alliance revenue is a growing contributor. Alliance revenue jumped 29% at constant currency to $1.699 billion in the first half, with Q2 alliance revenue up 33% to $874 million. That line captures AstraZeneca’s share of partnered products, particularly its collaboration with Daiichi Sankyo on antibody-drug conjugates like Enhertu and Datroway.

The United States is the largest market. The US represented 42% of product revenue at $12.9 billion, growing 8%. US growth is critical because American drug pricing generates the highest margins, and AstraZeneca has been expanding its US manufacturing and R&D presence.

The full-year 2025 base provides context. AstraZeneca reported total revenue of $58.739 billion for 2025, up 9% reported and 8% at constant currency, with reported EPS of $6.60, up 45%.

For the forecast, the first-half numbers show a business growing earnings at a double-digit pace with expanding margins. That combination rarely trades at a trailing multiple near 24 times unless the market has specific concerns. Those concerns lie in generics and the pipeline, covered below.

Therapy Areas: Oncology $14.1 Billion Up 15%, Rare Disease Up 11%, BioPharmaceuticals Down 5%

AstraZeneca’s growth is concentrated in two areas, and the split explains both the bull case and the bear case.

Oncology is the engine. Oncology revenue reached $14.1 billion in the first half, up 15% at constant currency. That makes oncology 46% of total revenue and the company’s fastest-growing large franchise. Tagrisso continues to show strong demand growth across indications and regions and is positioned as the backbone treatment across all stages of EGFR-mutated non-small cell lung cancer. The antibody-drug conjugate portfolio with Daiichi Sankyo adds a second growth layer.

Recent oncology data supports the franchise. AstraZeneca and Daiichi Sankyo announced that Enhertu met the primary endpoint in the DESTINY-Lung04 Phase III trial, showing a statistically significant improvement in progression-free survival as a first-line treatment for HER2-mutant advanced lung cancer. That expands Enhertu’s potential into earlier-line lung cancer. Not every readout succeeded: AstraZeneca discontinued the eVOLVE-Lung02 Phase III trial of volrustomig with chemotherapy in metastatic lung cancer with low PD-L1 expression.

Rare Disease is the second engine. Rare disease revenue reached $4.9 billion in the first half, up 11%, driven by continued patient demand across the portfolio. The Alexion franchise grew on demand for Ultomiris, both from patients new to complement inhibitors and from conversion from the older drug Soliris across generalized myasthenia gravis, neuromyelitis optica, atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria.

BioPharmaceuticals is the drag. That segment, covering cardiovascular, renal, metabolism, respiratory and immunology, generated $11.2 billion in the first half, down 5%, as the impact of generics on cardiovascular products was largely offset by growth in respiratory and immunology. Within respiratory, Fasenra expanded its share leadership in severe eosinophilic asthma, Breztri became the fastest-growing medicine in the triple-combination inhaler class, and Tezspire showed sustained demand growth.

The mix shift is the investment story. Oncology and rare disease are growing double digits, carry the highest margins and have long patent lives. BioPharmaceuticals is losing its older cardiovascular blockbusters to generics. Each year, the growing segments represent a larger share of revenue, so the overall growth rate should improve as the generic drag fades.

For the forecast, the therapy-area split shows AstraZeneca’s growth is healthy where it matters. Oncology at $14.1 billion growing 15% is a franchise worth well over half the company’s market value on its own.

Generics and China: Farxiga Down 11% and the Hidden 11% Growth Rate

AstraZeneca’s headline growth understates the strength of its business because of two specific headwinds.

The first is Farxiga. Farxiga revenue fell 11% at constant currency to $3.998 billion in the first half of 2026, reflecting the US loss of exclusivity. Farxiga, a diabetes and heart failure medicine, was one of AstraZeneca’s largest products, and generic entry in the United States is eroding its sales. Brilinta, the company’s blood thinner, has also lost exclusivity.

The second is China. Double-digit growth in oncology and rare disease offset headwinds from the Farxiga US loss of exclusivity and China’s volume-based procurement program. Under that program, China’s government buys drugs in bulk at steeply discounted prices, cutting revenue on affected products.

Stripping out the generic impact reveals the underlying growth. Total revenue grew 6% in the first half, but excluding Farxiga and Brilinta, which are affected by generics, revenue grew 11%. That 11% underlying growth rate is the number that justifies a growth multiple. It means the rest of the portfolio is expanding twice as fast as the headline suggests.

The generic headwind has a known shape. Patent expirations follow a predictable path: sales fall sharply in the first year after generic entry, then decline more slowly as the product approaches a stable residual base. As Farxiga’s revenue shrinks, its drag on overall growth diminishes. By 2027, the impact should be much smaller than in 2026.

China is less predictable. Volume-based procurement affects specific products at different times as China adds them to the program. AstraZeneca has significant exposure to China, which has historically been a growth market for the company. Further rounds of procurement could hit additional products.

The market has priced the headwinds harshly. A 6% headline growth rate looks pedestrian for a company trading at a premium, which helps explain the stock’s 21% decline over six months. Investors focusing on the 11% underlying rate see a different company.

For the forecast, the generic headwind is a 2026 problem that fades into 2027. As the gap between reported and underlying growth closes, reported growth should accelerate toward the double-digit underlying rate. That transition is one of the main reasons the stock looks cheap at current levels.

Guidance and the $80 Billion 2030 Ambition

AstraZeneca has held its guidance through a difficult year, and its long-term target frames the valuation case.

The company reconfirmed full-year 2026 guidance at constant exchange rates: total revenue is expected to increase by a mid-to-high single-digit percentage, and core EPS by a low double-digit percentage. The core tax rate is expected to be between 18% and 22%. First-half results tracked that guidance, with revenue up 6% and core EPS up 11%.

Currency should help. If exchange rates from July to December remain at June’s average levels, total revenue for 2026 would get a low single-digit percentage boost compared with constant-currency growth, while core EPS growth would be broadly similar. A weak dollar against European currencies earlier in the year inflated reported results; that tailwind may narrow as the dollar strengthens.

The long-term target is ambitious. AstraZeneca is on track to deliver its ambition of $80 billion in total revenue in 2030. That compares with $58.7 billion in 2025, implying revenue growth of 36% over five years, or roughly 6.4% compounded annually. Management said the target assumes both successes and setbacks in the pipeline.

The pipeline is the path to $80 billion. AstraZeneca expects more than 20 high-value readouts over the next 18 months. Since the fourth-quarter 2025 results, the company has secured 30 approvals in major regions. Each approval and successful readout adds to the revenue base needed to hit the 2030 target.

Management’s confidence matters. AstraZeneca’s leadership team, led by CEO Pascal Soriot, has a long track record of setting ambitious targets and meeting them. The company’s previous long-term targets were achieved ahead of schedule.

The guidance creates a clear benchmark for the October 30 report. Investors will look for third-quarter revenue growth consistent with the mid-to-high single-digit range and core EPS growth near 11%. A confirmation of full-year guidance would support the stock. Any cut would hit it hard given the recent pipeline setbacks.

For the forecast, the $80 billion target and low double-digit EPS growth support a higher valuation than current levels imply. At 23.75 times trailing earnings and growing core EPS at 11%, AstraZeneca trades at a reasonable growth-adjusted multiple for a company with its margin profile and pipeline depth.

The Pipeline Scorecard: Tozorakimab Wins, CARDIO-TTRansform and HICKORY Disappoint

AstraZeneca’s stock decline over the past six months tracks a series of mixed pipeline outcomes, and investors are recalibrating expectations for the remaining readouts.

The year started with a major win. AstraZeneca’s experimental COPD treatment tozorakimab succeeded in the OBERON and TITANIA Phase III trials, the first positive readout from a program of more than 20 major data releases planned for 2026. The drug blocks interleukin-33, a protein released in response to airway damage, and became the first IL-33-targeting biologic to show statistically significant reductions in COPD exacerbations across two replicate Phase III trials. Shares rose 4% that day.

Then came a setback in cardiology. In the first-half results, management said it was disappointed by the CARDIO-TTRansform outcome, a major cardiovascular trial. That miss removed a potential growth driver from the heart-disease portfolio and contributed to the stock’s decline from its highs.

The latest readout was mixed. On October 11, AstraZeneca reported that efzimfotase alfa, a next-generation enzyme replacement therapy for hypophosphatasia, missed the primary endpoint in the HICKORY Phase III trial. The drug produced a 17.05-meter improvement in the Six-Minute Walk Test at week 25 versus placebo, but the result had a p-value of 0.1675 and did not reach statistical significance. Several secondary measures were positive, including pain, fatigue, function and treatment satisfaction, with continued gains in the extension.

AstraZeneca is standing behind the drug. Peak sales guidance for efzimfotase alfa remains at $3 billion to $5 billion, and an FDA priority review is underway. The company argued that the trial was designed to reflect the full hypophosphatasia population, including adult-onset patients without clear skeletal manifestations, and that the drug offers dosing every two weeks with roughly 12 times fewer injections a year than the existing treatment, Strensiq.

The pattern matters for valuation. Each miss lowers the probability-weighted value of the remaining pipeline. With more than 20 readouts scheduled over 18 months, investors are now applying a higher discount to future successes. That discount is part of why the stock trades 24% below its high.

The heart-disease pipeline is drawing renewed interest. Wednesday’s double upgrade specifically cited investor focus returning to AstraZeneca’s heart-disease pipeline, suggesting that the market may have oversold the cardiovascular franchise after the CARDIO-TTRansform miss.

For the forecast, the pipeline is a source of both risk and upside. At current valuations, the market prices in a meaningful failure rate. Positive readouts over the next 18 months would push the stock back toward its highs.

Summit Therapeutics: A $2 Billion Bet on Ivonescimab and the ADC Combination Strategy

AstraZeneca’s largest strategic move of the autumn targets the future of cancer treatment, and it shapes the long-term oncology case.

AstraZeneca completed its $2 billion equity investment in Summit Therapeutics on October 5. The investment will accelerate development of ivonescimab, a first-in-class bispecific antibody targeting PD-1 and VEGF, in combination with antibody-drug conjugates across tumor types. The investment was structured through convertible preferred shares, and on conversion AstraZeneca would hold about 12.0% of Summit’s outstanding common stock.

The collaborations extend across AstraZeneca’s portfolio. The companies will study ivonescimab with AstraZeneca’s sonesitatug vedotin in gastrointestinal cancers, with jointly funded studies sponsored by AstraZeneca. A separate non-binding memorandum of understanding covers combinations of ivonescimab with other AstraZeneca cancer medicines, including antibody-drug conjugates. On October 2, AstraZeneca and Daiichi Sankyo entered a clinical collaboration with Summit to evaluate Datroway in combination with ivonescimab across multiple tumor types, including lung and breast cancers.

The strategic logic is combination therapy. Antibody-drug conjugates deliver chemotherapy directly to cancer cells, while bispecific antibodies like ivonescimab combine immune activation with blocking tumor blood supply. Combining the two could produce better outcomes than either alone, particularly in lung cancer, where AstraZeneca already holds a leading position with Tagrisso and Enhertu.

The deal structure limits risk. AstraZeneca is paying for what looks like a de-risked asset, and by taking equity, it captures both drug economics and stock upside if Summit is revalued. The structure lets AstraZeneca pursue bigger indications and earlier-line use without handing away its core assets.

The market reacted positively. When AstraZeneca announced the investment, the FTSE 100’s pharmaceutical sector rose 1.5%, with AstraZeneca up 1.7% to a two-month high. Since then, the stock gave back those gains on the HICKORY miss before Wednesday’s rebound.

The broader industry context matters. Big pharma has been striking deals for Chinese-developed drugs, and ivonescimab originated with China’s Akeso before Summit licensed rights for major markets. AstraZeneca’s investment positions it at the center of one of the most closely watched cancer drug classes.

For the forecast, the Summit deal strengthens the oncology growth case that underpins the $80 billion target. It will not affect near-term earnings, but successful combination trials in 2027 and 2028 could add meaningful revenue by the end of the decade.

US Expansion: Kendall Square, a $50 Billion Commitment and the NYSE Listing

AstraZeneca is reshaping its geographic footprint, with the United States at the center.

On October 5, AstraZeneca opened a new global strategic R&D center in Kendall Square, Cambridge, Massachusetts. The company is spending more than $1 billion on the 570,000-square-foot facility, part of a stated $50 billion US investment program. CEO Pascal Soriot said the hope is that the new site will enable faster and better development of new products.

The US investment serves several purposes. The United States is AstraZeneca’s largest market, representing 42% of product revenue at $12.9 billion and growing 8%. Building R&D and manufacturing capacity in the US positions the company closer to its largest customers, its most important regulator and the deepest pool of biotech talent. It also reduces exposure to US tariff and drug-pricing policy risks by increasing domestic investment.

The listing change reinforces the US focus. AstraZeneca is listed in London, Stockholm and New York, with its US shares trading on the New York Stock Exchange. The primary listing remains on the London Stock Exchange. The NYSE listing broadens access for US investors and may support the valuation over time, as US-listed pharmaceutical companies have historically traded at higher multiples than their European peers.

The valuation gap with US peers is significant. AstraZeneca trades at a trailing P/E of 23.75. Large US pharmaceutical companies with similar growth profiles have traded at higher multiples, particularly those exposed to high-growth areas like obesity and oncology. A deeper US investor base could narrow that gap.

The timing of the Kendall Square opening and the US investment program also reflects political realities. The US administration has pushed pharmaceutical companies to invest domestically, and companies that commit to large US investments have generally fared better in trade and pricing negotiations.

For the forecast, the US expansion is a long-term positive. It strengthens AstraZeneca’s position in its most important market, reduces policy risk and may support a higher valuation multiple as the company’s investor base shifts toward the United States.

Valuation: 23.75 Times Earnings, a 2.00% Yield and a 0.21 Beta

AstraZeneca’s valuation looks attractive against its growth, and its defensive characteristics are particularly valuable in the current market.

The stock trades at a trailing price-to-earnings ratio of 23.75 and a dividend yield of 2.00%. With core EPS growing at a low double-digit pace, that implies a growth-adjusted valuation near 2 times. For a company with an 84% gross margin, a $58.7 billion revenue base and a credible path to $80 billion, that multiple is reasonable rather than stretched.

The dividend is well covered. AstraZeneca pays a dividend of $0.795 per share, with the most recent ex-dividend date on August 7. The stock maintains a dividend yield near 1.93% to 2.00% with a low payout ratio, supporting a stable income profile as the company secures major new collaborations and funding.

The beta is exceptionally low. AstraZeneca’s beta stands at 0.21, meaning the stock historically moves only one-fifth as much as the broader market. That low correlation explains why the shares rose on Wednesday while the market fell. In a period of rising Treasury yields and inflation concerns, low-beta, cash-generative stocks attract capital fleeing high-multiple growth names.

The market capitalization is substantial. AstraZeneca’s US market capitalization stood at $241.7 billion on October 13 and $247.6 billion on October 9. In London, the market capitalization reached £184.5 billion after Wednesday’s gain. AstraZeneca remains the most valuable company on the FTSE 100.

The consensus price target signals upside. The average analyst price target stands at $207.16, 28.2% above Wednesday’s price. In London, recent targets of 17,500p and 18,600p sit 42% and 51% above the 12,286p close. Even after the stock’s decline, the sell side broadly views AstraZeneca as undervalued.

The comparison with growth stocks is stark. On the same day, AMD traded at 148 times trailing earnings and Nvidia at 28 times. AstraZeneca at 23.75 times trailing earnings, growing EPS at 11%, offers a more conservative profile with lower volatility.

For the forecast, valuation supports the bullish case. The stock is priced for disappointment after a series of pipeline setbacks. Any improvement in the pipeline narrative or confirmation of guidance on October 30 would likely trigger a re-rating.

The Drawdown: Down 24% From the High, 21% in Six Months, 10.6% Year to Date

AstraZeneca’s recent price history shows how far the stock has fallen and where buyers have stepped in.

The US-listed shares hit their 52-week high of $212.71 earlier in the year. Even as late as the tozorakimab readout, the stock traded at $191.72, with a 12-month range at that time of $122.48 to $212.71. From the peak to Wednesday’s $161.59, the shares have lost 24%. In London, the decline from the 15,732p high to 12,286p is 22%.

The decline accelerated over the past six months. Shares were down 21% over the six months before the HICKORY readout. As of October 2, the US-listed stock was down 10.60% year to date. That means the stock entered 2026 near $180 and rose toward $212 before giving back all of its gains and more.

The October path shows the final leg lower. The shares slid from the $166 to $169 area toward the mid-$150s over the past few weeks. The stock traded at $159.67 on October 9, $158.61 after a 1.33% gain on another session, $158.33 on October 12 and $155.82 on October 13. The London close was 11,998p on October 9 and 11,896p on October 13, with Tuesday trading between 11,884p and 12,310p.

The low of the move has held. The 52-week low of $153.41 sits 1.6% below Tuesday’s close. Buyers defended that zone during the HICKORY selloff and stepped in aggressively on Wednesday. A double bottom near $153 to $156 would be a constructive technical pattern.

The decline has been driven by specific events. The CARDIO-TTRansform miss, the HICKORY result, Farxiga generic erosion and China procurement pressure all hit the stock over a short period. Each piece of bad news came while the broader market was focused on AI and growth stocks, leaving defensive pharma out of favor.

That environment is shifting. With the 10-year Treasury at 5.278% and investors questioning the valuations of AI stocks, defensive sectors like healthcare are attracting renewed interest. Wednesday’s sector rotation could mark the start of a broader recovery for large-cap pharma.

For the forecast, the 24% drawdown has reset expectations to a low level. The stock has absorbed multiple setbacks and found support. That creates an asymmetric setup where good news has more impact than bad.

Chart Map: $153.41 Low, $162 Breakout Test, $166–169 Resistance

The technical picture improved on Wednesday, but AZN still needs to clear overhead resistance to confirm a reversal.

On the US listing, support begins at Wednesday’s session low of $158.31. Below that, Tuesday’s close of $155.82 forms the next support level, and the 52-week low of $153.41 marks the floor. A daily close below $153.41 would break the base and open the door to a deeper decline.

Resistance starts at $161.72, Wednesday’s early high, and $162.14, the level reached by midday. Above that, the $166 to $169 zone is the key barrier, marking where the stock broke down earlier in October. A reclaim of $169 would signal that the October selloff has run its course and open a path toward $175 and higher. The average analyst target of $207.16 sits well above.

In London, the picture is similar. Support sits at 11,816p, Wednesday’s low, and 11,694p, a level identified as key support earlier this month. Resistance stands at 12,310p, Tuesday’s high, and the 12,286p close. The stock traded below its key moving averages before Wednesday’s move, with mixed technical signals and a projected range of 11,816p to 12,231p dominated by bearish longer-term pressure. Wednesday’s close at 12,286p broke above the top of that projected range.

Momentum is turning. A 3.70% gain on a low-beta stock is a significant move, equivalent to a much larger move in a typical stock. If follow-through buying lifts the shares above $166 in the coming sessions, the October downtrend would be broken.

Volume confirms interest. The US-listed shares had traded 973,761 shares by late morning. In London, 2.15 million shares traded on Tuesday, and Wednesday’s rally drew strong participation.

The moving averages remain overhead. AstraZeneca trades below its key moving averages on both short and longer timeframes. Those averages will act as resistance as the stock attempts to recover, and a sustained move above them would confirm a trend change.

For the forecast, the levels are clear. A close above $169 targets $175, with the consensus $207 target as a longer-term objective. A close below $153.41 would invalidate the bullish view and target lower levels.

Catalysts: Q3 Results October 30, 20-Plus Readouts and the Rate Backdrop

The next weeks and months carry several events that will decide whether AstraZeneca’s rebound becomes a sustained recovery.

October 30: third-quarter results. This is the most important near-term catalyst. Investors will look for revenue growth consistent with the mid-to-high single-digit guidance, core EPS growth near 11%, continued oncology strength above 15%, and an update on the Farxiga generic decline. A reaffirmation of full-year guidance and the $80 billion 2030 target would support a move toward $169. Any guidance cut would push the stock back toward its lows.

Ongoing: pipeline readouts. AstraZeneca expects more than 20 high-value readouts over the next 18 months. Positive results in oncology, particularly antibody-drug conjugates and combinations, would strengthen the growth case. Any readout in the heart-disease pipeline will draw particular attention after Wednesday’s upgrade focused on that area.

Ongoing: efzimfotase alfa regulatory review. The FDA priority review for the hypophosphatasia drug continues. Approval despite the HICKORY primary endpoint miss would validate management’s view of the $3 billion to $5 billion peak sales potential.

Ongoing: Summit collaboration progress. Early data from ivonescimab combinations with AstraZeneca’s ADCs will shape the long-term oncology outlook.

Macro backdrop: The Fed decides on October 28, two days before AstraZeneca’s results. A hawkish Fed would keep pressure on growth stocks and support the defensive rotation into healthcare. In the UK, the Bank of England decides on November 5, and easing rate expectations would support the FTSE 100.

US policy: Drug pricing and tariff policy in the United States remains a background risk for all pharmaceutical companies. AstraZeneca’s $50 billion US investment program positions it relatively well.

Currency: A stronger dollar would reduce the translation benefit to reported revenue, though core EPS growth is expected to be broadly similar to constant-currency growth.

The sequence favors AstraZeneca. The macro backdrop supports defensive stocks, and the October 30 report gives management a platform to reset the narrative after a difficult six months.

AstraZeneca Stock Forecast and Verdict: Bullish From the Base, $169 Then $175 Targets

The verdict for AstraZeneca is bullish from current levels. AZN at $161.59 has rallied 3.70% off a base just above its $153.41 52-week low, driven by a defensive rotation into healthcare, a double upgrade from Sell to Buy and easing UK rate expectations. On a day when the S&P 500 fell 0.82% and the Nasdaq dropped 1.14%, AstraZeneca’s low beta of 0.21 and stable cash flows made it a beneficiary rather than a casualty of rising Treasury yields.

The fundamentals support the move. First-half revenue reached $30.672 billion, up 6% at constant currency and 11% excluding generic-affected Farxiga and Brilinta. Core EPS grew 11% to $5.21, with Q2 core EPS up 18%. Oncology revenue grew 15% to $14.1 billion, and core gross margin improved to 84% in the second quarter. Management reaffirmed full-year guidance for mid-to-high single-digit revenue growth and low double-digit core EPS growth, and its $80 billion 2030 revenue ambition.

The valuation leaves room for upside. At 23.75 times trailing earnings with a 2.00% dividend yield, AstraZeneca trades at a reasonable multiple for a company growing EPS at 11%. The stock sits 24% below its $212.71 high and 28.2% below the average analyst target of $207.16.

The risks are pipeline-specific. The CARDIO-TTRansform miss and the HICKORY primary endpoint failure have raised doubts about the remaining readouts. Farxiga generics and China procurement will continue to weigh on 2026 reported growth. A guidance cut on October 30 would invalidate the bullish view.

The base case is a move toward the $166 to $169 resistance zone into the October 30 report, a 2.7% to 4.6% gain. A clean third-quarter print with reaffirmed guidance would open a path to $175, an 8.3% gain. Longer term, the consensus target of $207.16 represents the full recovery case.

The downside is defined. A daily close below the $153.41 52-week low, a 5.1% decline from current levels, would break the base and invalidate the bullish forecast.

Forecast: bullish, with a $169 near-term target and $175 on a strong October 30 report. Support at $155.82 and $153.41 defines the risk. AstraZeneca offers growth at a reasonable price, a well-covered dividend and defensive characteristics in a market where rising yields are punishing high-multiple stocks.

That's TradingNEWS